Advertisement

Topics

Orbsen Therapeutics Company Profile

00:58 EDT 16th June 2019 | BioPortfolio

Orbsen Therapeutics, Ltd. is a leading company in the development of regenerative medicine therapies across a range of diseases and medical conditions. Founded in 2006, Orbsen Therapeutics Ltd., is a privately held company led by global leaders in the field of regenerative medicine. The company, which spun-out from Ireland’s Regenerative Medicine Institute at the National University or Ireland, Galway, has developed proprietary technologies that enables the isolation of pure and allogeneic stromal cells from human tissues which can be purified from a single donor, expanded and frozen to generate multiple doses of a high-margin, “off the shelf” therapeutic product.


News Articles [870 Associated News Articles listed on BioPortfolio]

Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland

Progress in company's product pipeline requires move to larger facilities GALWAY, Ireland (PRWEB) April 02, 2019 Orbsen Therapeutics, a biotechnology company focused on the discovery, development...

Sarepta Therapeutics Acquires Myonexus Therapeutics For $165 Million

WASHINGTON (dpa-AFX) - Sarepta Therapeutics Inc. (SRPT), Wednesday said it has exercised its option to acquire Myonexus Therapeutics, a clinical-stage biotechnology company developing transformati...

Roche’s Genentech agrees to buy Jecure Therapeutics

Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CE...

Indalo Therapeutics Names Robert Jacks President & CEO

Indalo Therapeutics has appointed Robert Jacks to serve as president and CEO. Jacks was most recently president and chief financial officer of Symbiomix Therapeutics, which was acquired by Lupin in 20...

e-Therapeutics - The benefits of partnerships and cost control

Edison Investment Research - Pharmaceuticals & healthcare - e-Therapeutics: e-Therapeutics' (ETX) FY19 results demonstrated continued financial prudence and its focus on partnering, out-licensing a...

Vertex Expands Collaboration with CRISPR Therapeutics and Acquires Exonics Therapeutics

BOSTON & WATERTOWN, Mass. & ZUG, Switzerland–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the company is enhancing its gene editing capab...

Nohla’s Christianson Joins Rainier Therapeutics as Chief Technical Officer

Gary Christianson has been appointed chief technical officer of San Leandro, CA-based Rainier Therapeutics. Christianson was most recently chief operating officer at Nohla Therapeutics in Seattle. His...

Shield Therapeutics - Fortified for growth

Edison Investment Research - Pharmaceuticals & healthcare - Shield Therapeutics: Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulatio...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [477 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

Clinical Trials [179 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1338 Associated Companies listed on BioPortfolio]

Orbsen Therapeutics

Orbsen Therapeutics, Ltd. is a leading company in the development of regenerative medicine therapies across a range of diseases and medical conditions. Founded in 2006, Orbsen The...

Orbsen Therapeutics Limited

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Orbsen Therapeutics" on BioPortfolio

We have published hundreds of Orbsen Therapeutics news stories on BioPortfolio along with dozens of Orbsen Therapeutics Clinical Trials and PubMed Articles about Orbsen Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Orbsen Therapeutics Companies in our database. You can also find out about relevant Orbsen Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...


Corporate Database Quicklinks



Searches Linking to this Company Record